The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
Open accessAbstract
BACKGROUND: Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized phase II trial evaluated SABR in a group of patients with a small burden of oligometastatic disease (mostly with 1-3 metastatic lesions), and found that SABR was associated with benefits in progression-free survival and overall survival. The goal of this phase III trial is to assess the impact of SABR in patients with 4-10 metastatic cancer lesions. METHODS: One hundred and fifty-nine patients will be randomized in a 1:2 ratio between the control arm (consisting of standard of care palliative-intent treatments), and the SABR arm (consisting of standard of care treatment + SABR to all sites of known disease). Randomization will be stratified by two factors: histology (Group 1: prostate, breast, or renal; Group 2: all others), and type of pre-specified systemic therapy (Group 1: immunotherapy/targeted; Group 2: cytotoxic; Group 3: observation). SABR is to be completed within 2 weeks, allowing for rapid initiation of systemic therapy. Recommended SABR doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions, chosen to minimize risks of toxicity. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, time to development of new metastatic lesions, quality of life, and toxicity. Translational endpoints include assessment of circulating tumor cells, cell-free DNA, and tumor tissue as prognostic and predictive markers, including assessment of immunological predictors of response and long-term survival. DISCUSSION: This study will provide an assessment of the impact of SABR on clinical outcomes and quality of life, to determine if long-term survival can be achieved for selected patients with 4-10 oligometastatic lesions. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03721341 . Date of registration: October 26, 2018.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emerging Biological Principles of Metastasis
Lambert, A. W., Pattabiraman, D. R., & Weinberg, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.11.037 · Cited by 3,067
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Self-citationLong-term results of lung metastasectomy: Prognostic analyses based on 5206 cases
Pastorino, U., Buyse, M., Friedel, G., Ginsberg, R. J., Girard, P., Goldstraw, P., Johnston, M., McCormack, P., Pass, H., & Putnam, J. B. (1997) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(97)70397-0 · Cited by 1,529
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Gomez, D. R., Blumenschein, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30532-0 · Cited by 1,086
Self-citationIyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Westover, K. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3501 · Cited by 1,047
Cited by
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00818 · Cited by 1,300
Self-citationGerstberger, S., Jiang, Q., & Ganesh, K. (2023) · Cell · doi:10.1016/j.cell.2023.03.003 · Cited by 913
Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies
Miller, E. D., Hitchcock, K. E., & Romesser, P. B. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00900-5 · Cited by 31
Metadata
- Authors
- Palma, D. A., Olson, R., Harrow, S., Correa, R. J. M., Schneiders, F., Haasbeek, C. J. A., Rodrigues, G. B., Lock, M., Yaremko, B. P., Bauman, G. S., Ahmad, B., Schellenberg, D., Liu, M., Gaede, S., Laba, J., Mulroy, L., Senthi, S., Louie, A. V., Swaminath, A., Chalmers, A., Warner, A., Slotman, B. J., de Gruijl, T. D., Allan, A., & Senan, S.
- Venue
- BMC Cancer
- Published
- 2019-08-19
- Volume
- 19
- Issue
- 1
- Pages
- 816-816
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W4232184817
- Cited by
- 260
- References
- 29
- FWCI
- 28.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. https://app.cochat.ai/papers/10.1186/s12885-019-5977-6
- The paper
- Palma, D. A., Olson, R., Harrow, S., Correa, R. J. M., Schneiders, F., Haasbeek, C. J. A., Rodrigues, G. B., Lock, M., Yaremko, B. P., Bauman, G. S., Ahmad, B., Schellenberg, D., Liu, M., Gaede, S., Laba, J., Mulroy, L., Senthi, S., Louie, A. V., Swaminath, A., . . . Senan, S. (2019). Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. https://doi.org/10.1186/s12885-019-5977-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.